Why did you use the 2024 guidelines in an earlier response
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
I apologize for any confusion. You are correct to question this. Looking at the provided source materials, I notice they are labeled as "NCCN Guidelines for Patients® Early-Stage Prostate Cancer, 2024." However, I should not have broadly applied these prostate cancer-specific guidelines to other cancer types.
According to the NCCN Guidelines shown in the sources:
- These are specifically "NCCN Guidelines for Patients® for Early-Stage Prostate Cancer, Version 4.2024 — [date removed]"
- They are focused on prostate cancer management and treatment
- They should not be applied to other cancer types
Since you indicated you have a different type of cancer ("other"), I should not have referenced these prostate cancer-specific guidelines in responding to your questions. Instead, I should:
- Ask what specific type of cancer you have
- Only cite guidelines that are relevant to your specific cancer type
- Acknowledge when I don't have access to the appropriate guidelines for your situation
Would you be willing to share what type of cancer you have so I can provide more relevant information? I want to ensure I'm giving you accurate guidance based on the appropriate NCCN Guidelines for your specific condition.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ